Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study

Sadeleştirilmiş öğe sayfası
dc.contributor.authorUrun, Yuksel
dc.contributor.authorYasar, H. Arzu
dc.contributor.authorTurna, Hande
dc.contributor.authorEsin, Ece
dc.contributor.authorSedef, A. Murat
dc.contributor.authorAlkan, Ali
dc.contributor.authorOksuzoglu, Berna
dc.contributor.authorOzdemir, Nuriye
dc.contributor.authorSendur, M. A. Nahit
dc.contributor.authorSezer, Ahmet
dc.contributor.authorKilickap, Saadettin
dc.contributor.authorUtkan, Gungor
dc.contributor.authorAkman, Tulay
dc.contributor.authorAkbulut, Hakan
dc.contributor.authorCelik, Ismail
dc.contributor.authorAbali, Huseyin
dc.date.accessioned2025-10-16T15:22:49Z
dc.date.issued2019
dc.identifier.doi10.1177/1078155218805539
dc.identifier.otherWOS:000482977300016
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/7892
dc.publisherSAGE PUBLICATIONS LTD
dc.sourceJOURNAL OF ONCOLOGY PHARMACY PRACTICE
dc.subjectIpilimumab
dc.subjectmelanoma
dc.subjectprognostic factors
dc.subjectabsolute lymphocytes count
dc.titlePrognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study
dc.typeArticle

Dosyalar

Koleksiyonlar

WOS